Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A...

por Song, Yong, Wu, Yi-Long, Cao, Le-Jie, Chen, Jian-Hua, Ma, Zhi-Yong, Cui, Jiu-Wei, Wang, Jie, Liu, Hong-Bing, Ding, Jing-Yan, Hu, Min
Publicado 2019